在抗肿瘤治疗中靶向细胞周期蛋白依赖性激酶。
Targeting cyclin-dependent kinases in anti-neoplastic therapy.
机构信息
ManRos Therapeutics, Centre de Perharidy, 29680 Roscoff, France.
出版信息
Curr Opin Cell Biol. 2013 Dec;25(6):772-9. doi: 10.1016/j.ceb.2013.08.004. Epub 2013 Sep 6.
PMID:24011867
Abstract
Cell cycle progression is controlled by sequential activation of cyclin-dependent kinases (CDKs), which are often deregulated in cancer. Consequently numerous pharmacological inhibitors of CDKs have been developed with the aim of treating cancers. The article briefly reviews CDK inhibitors and their use to treat cancers, with specific focus on the use of biomarkers and drugs combination to improve their therapeutic efficacy.
摘要
细胞周期的进展受细胞周期蛋白依赖性激酶（CDKs）的顺序激活控制，而 CDK 在癌症中经常失调。因此，已经开发了许多 CDK 的药理学抑制剂，旨在治疗癌症。本文简要综述了 CDK 抑制剂及其在癌症治疗中的应用，特别关注了使用生物标志物和药物联合来提高其治疗效果。
Zotero 插件